| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, March 30 /PRNewswire/ -- BrainCells Inc. (BCI), a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of neurologic conditions, announced today the appointment of Dr. Philip Jochelson as chief medical officer and Jason Levin as chief business officer. Both have extensive experience in the biopharmaceutical industry with specific expertise in building neurology assets for success. The two will serve in integral roles managing clinical programs and licensing/partnership agreements for BrainCells' pipeline of neurologic compounds.
"We have two compounds in Phase 2 trials which will produce the first ever data on clinical impact from targeting neurogenesis for therapeutic benefit," said Jim Schoeneck, BrainCells CEO. "We have confidence in our drug candidates based on what we know about their neurogenic properties from our platform that enables us to conduct comparison analysis between multiple compounds, experiment with various pathways, analyze complex pharmacology, and image and measure the neurogenic process. Philip and Jason are top caliber people that come at a pivotal time in the company's development."
Dr. Jochelson will replace Steve Targum as chief medical officer. His primary focus will be on progression of the company's clinical programs and expansion of the pipeline into broader indications. Dr. Jochelson was most recently senior vice president of development and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical company, where he was responsible for the development of all product candidates while also supporting financing and business development activities. Prior to that, he was at Neurocrine Biosciences where he led several clinical development programs. Through his combined experience, he has designed and implemented multiple clinical studies across all phases of develo
'/>"/>
| SOURCE BrainCells Inc. Copyright©2009 PR Newswire. All rights reserved |